Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven G Deeks

Showing results (501-510 of 663) with videos related to

Pageof 67
Sort By:
The Journal of Infectious Diseases|February 28, 2002
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patientsConstance A Benson, Steven G Deeks, Scott C Brun, et al.
The Journal of Infectious Diseases|May 28, 2014
Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infectionNetanya G Sandler, Xinyan Zhang, Ronald J Bosch, et al.
The Journal of Infectious Diseases|December 5, 2019
Human Immunodeficiency Virus (HIV)-Infected CCR6+ Rectal CD4+ T Cells and HIV Persistence On Antiretroviral TherapyJenny L Anderson, Gabriela Khoury, Rémi Fromentin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2021
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency VirusVincent C Marconi, Carlee Moser, Christina Gavegnano, et al.
Nature Medicine|April 1, 2008
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individualsSunil K Ahuja, Hemant Kulkarni, Gabriel Catano, et al.
AIDS (London, England)|July 14, 2018
Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1Christina C Chang, Vivek Naranbhai, Jared Stern, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 12, 2020
Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective studyTimothy J Henrich, Corinna Schreiner, Cheryl Cameron, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2024
HIV-1 control in vivo is related to the number but not the fraction of infected cells with viral unspliced RNAAdam A Capoferri, Ann Wiegand, Feiyu Hong, et al.
Medrxiv : the Preprint Server for Health Sciences|May 5, 2025
Persistent immune dysregulation and metabolic alterations following SARS-CoV-2 infectionSilvia Lucena Lage, Katherine Bricker-Holt, Joseph M Rocco, et al.
Plos Pathogens|January 23, 2016
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialSergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, et al.
Pageof 67

Showing results (501-510 of 663) with videos related to

Sort By:
Pageof 67
The Journal of Infectious Diseases|February 28, 2002
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patientsConstance A Benson, Steven G Deeks, Scott C Brun, et al.
The Journal of Infectious Diseases|May 28, 2014
Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infectionNetanya G Sandler, Xinyan Zhang, Ronald J Bosch, et al.
The Journal of Infectious Diseases|December 5, 2019
Human Immunodeficiency Virus (HIV)-Infected CCR6+ Rectal CD4+ T Cells and HIV Persistence On Antiretroviral TherapyJenny L Anderson, Gabriela Khoury, Rémi Fromentin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2021
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency VirusVincent C Marconi, Carlee Moser, Christina Gavegnano, et al.
Nature Medicine|April 1, 2008
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individualsSunil K Ahuja, Hemant Kulkarni, Gabriel Catano, et al.
AIDS (London, England)|July 14, 2018
Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1Christina C Chang, Vivek Naranbhai, Jared Stern, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 12, 2020
Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective studyTimothy J Henrich, Corinna Schreiner, Cheryl Cameron, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2024
HIV-1 control in vivo is related to the number but not the fraction of infected cells with viral unspliced RNAAdam A Capoferri, Ann Wiegand, Feiyu Hong, et al.
Medrxiv : the Preprint Server for Health Sciences|May 5, 2025
Persistent immune dysregulation and metabolic alterations following SARS-CoV-2 infectionSilvia Lucena Lage, Katherine Bricker-Holt, Joseph M Rocco, et al.
Plos Pathogens|January 23, 2016
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialSergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, et al.
Pageof 67